AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas – respiratory, inflammation, autoimmune disease (RIA); cardiovascular and metabolic disease (CVMD) and oncology – as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.
In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.
What is BI doing specifically in respiratory medicine?
Since launching its first respiratory medicine in 1921, BI has made available to patients many important products for diseases with a high unmet medical need– including the most widely prescribed COPD maintenance treatment in the UK Spiriva® (tiotropium).
2015 was a landmark year for the BI Respiratory therapeutic area. OFEV® (nintedanib) and Spiolto® Respimat® (tiotropium and olodaterol) received marketing authorisation across the European Union (EU) and were made available in the UK in January and June respectively. Our vision is to ensure that treatments are not only innovative, but also make a meaningful difference and bring lasting improvements to the lives of patients suffering from respiratory illnesses.
Research beyond symptomatic treatments
The new BI R&D strategy will advance the development of drugs for hard-to-treat or as yet untreatable diseases. BI plans to invest eleven billion euros in the development of innovative drugs over the next five years. Pre-clinical research will focus more intensively on innovative therapeutic approaches, such as tissue remodelling and tissue regeneration. These new innovations highlight BI’s continued commitment to respiratory therapies.
The goal is for new treatments for patients with COPD and asthma – but also pioneering therapies for rarer indications with a high unmet medical need, such as acute respiratory distress syndrome (ARDS) and cystic fibrosis. The scientific results of BI’s research will be very important for the development of the next generation of medical breakthroughs for the treatment of respiratory conditions.
For more than 45 years, GSK has been helping patients with respiratory disease better manage their condition; to feel healthier and lead the life they want. Investing more than any other company and working in collaboration with the scientific community, we remain at the cutting-edge of scientific research into respiratory diseases. We research and develop innovative medicines aimed at helping to treat patients’ symptoms and reduce the risk of their disease worsening. We have the broadest portfolio of once-daily medicines in a single inhaler type; our Ellipta® inhaler. This is the result of more than ten years of development incorporating patient and physician feedback to ensure it is not only effective but also easy-to-use.
Through ongoing scientific research in new and existing areas, and external partnerships, we will continue to innovate in the development of medicines and inhalers that have real value to patients and physicians
Pfizer and Novartis collaborate as the Novartis-Pfizer alliance to improve the wellness of patients living with Chronic Obstructive Pulmonary Disease (COPD)
“At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global healthcare portfolio includes biologic and small molecule medicines and vaccines, as well as many of the world’s best-known consumer products. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. Novartis products are available in more than 180 countries around the world. For more information, please visit www.novartis.com
You are viewing the text version of this site.
Need help? check the requirements page.